Subcutaneous · GLP-1 / GIP dual
CT-868
4 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
4
Active
0
Recruiting
0
Completed
4
Sites
28
Countries
2
Endpoints
45
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
4
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
4 of 4
| Asset / Population | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT06062069A Study of CT-868 in Type 1 Diabetes Mellitus | CT-868 Obesity / overweight, Type 1 diabetes | BMI ≥27 | Ph 2 | Completed | 22 | Jul 2025 | — | |
| NCT05110846A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus | CT-868 Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 2 | Completed | 5 | Feb 2023 | — | |
| NCT04973111A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose | CT-868 Obesity / overweight, Type 2 diabetes | BMI 30-35 | Ph 1 | Completed | 1 | Apr 2022 | — | |
| NCT05794581A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes | CT-868, Liraglutide Obesity / overweight, Type 1 diabetes | BMI 25-35 | Ph 1 | Completed | 1 | Mar 2024 | — |